A Phase 1 interventional study of Aticaprant and Placebo in Schizophrenia, sponsored by Janssen Research & Development, LLC. Recruiting at 8 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 121st largest by planned enrollment of the 176 interventional ones that give a count, is the only one that started in 2026, is one of 42 in phase 1, and was the 206th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 12 · Phase 3 74 · Phase 4 47
First in 1996; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is close to the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 165 across the 176 interventional studies, 541 across the 30 observational. Of the 203 that completed or were terminated, 57 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Schizophrenia by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07615426Janssen Research & Development, LLCA Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia | 2027-06-21 |
Add it to your calendar (.ics) → With an account.
Among the 206 studies in Schizophrenia by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive aticaprant during the double blind (DB) treatment phase.
Drug: Aticaprant
Participants will receive placebo during the DB treatment phase.
Drug: Placebo
Participants will receive aticaprant during the double blind (DB) treatment phase.
Also known as: JNJ-67953964
Participants will receive placebo during the DB treatment phase.
Screen Pass Rate
Screening pass rate of participants will be reported.
Time frame: Up to 28 days
Exploratory Assessment-Specific Completion Rate
Assessment specific completion rate of participants will be reported.
Time frame: Up to 126 days
Total Assessment Completion Rate
Time frame: Up to 126 days
Study Completion Rate
Time frame: Up to 126 days
Adverse Events (AEs) Including AEs of Special Interest (AESI)
Time frame: Up to 126 days
Number of Participants with Abnormalities in Vital Signs
Time frame: Up to 126 days
Number of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)
Time frame: Up to and including 85 days
Number of Participants with Abnormalities in Laboratory Parameters
Time frame: Up to and including 85 days
Number of Participants Reporting Changes in Body Weight
Time frame: Up to and including 85 days
Number of Participants Reporting Changes in Body Mass Index (BMI)
Time frame: Up to and including 85 days
Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) Over Time
The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the occurrence and intensity of suicidal thoughts and suicidal behaviors.
Time frame: Up to 126 days
Extrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total Score
Time frame: Up to and including 85 days
Not enrolling at this site.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.jnj.com
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 15 months is above that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Dec 2027, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aticaprant
Janssen Research & Development, LLC →